Ionis Pharmaceuticals, Inc. (IONS)

Market Cap	7.16B
Revenue (ttm)	615.03M
Net Income (ttm)	-409.45M
Shares Out	143.47M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	90.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	715,887
Open	50.12
Previous Close	49.94
Day's Range	49.33 - 50.12
52-Week Range	32.69 - 51.89
Beta	0.49
Analysts	Hold
Price Target	50.38 (+1.84%)
Earnings Date	Nov 2, 2023

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 1991
• Employees: 796
• Stock Exchange: NASDAQ
• Ticker Symbol: IONS

Financial Performance

In 2022, IONS's revenue was $587.37 million, a decrease of -27.53% compared to the previous year's $810.46 million. Losses were -$269.72 million, 843.2% more than in 2021.

Analyst Forecast

According to 13 analysts, the average rating for IONS stock is "Hold." The 12-month stock price forecast is $50.38, which is an increase of 1.84% from the latest price.

Price Target

$50.38

(1.84% upside)

Analyst Consensus: Hold